Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis
Paola Guglielmelli(Azienda Ospedaliero-Universitaria Careggi)
Cited by 149
Related Papers
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Mutations and thrombosis in essential thrombocythemia
|Blood Cancer Journal|2021|41
Genetic lesions disrupting calreticulin 3′‐untranslated region in <scp>JAK2</scp> mutation‐negative polycythemia <scp>vera</scp>
|American Journal of Hematology|2020|9